Van Dijck Patrick, Sjollema Jelmer, Cammue Bruno P, Lagrou Katrien, Berman Judith, d'Enfert Christophe, Andes David R, Arendrup Maiken C, Brakhage Axel A, Calderone Richard, Cantón Emilia, Coenye Tom, Cos Paul, Cowen Leah E, Edgerton Mira, Espinel-Ingroff Ana, Filler Scott G, Ghannoum Mahmoud, Gow Neil A R, Haas Hubertus, Jabra-Rizk Mary Ann, Johnson Elizabeth M, Lockhart Shawn R, Lopez-Ribot Jose L, Maertens Johan, Munro Carol A, Nett Jeniel E, Nobile Clarissa J, Pfaller Michael A, Ramage Gordon, Sanglard Dominique, Sanguinetti Maurizio, Spriet Isabel, Verweij Paul E, Warris Adilia, Wauters Joost, Yeaman Michael R, Zaat Sebastian A J, Thevissen Karin
VIB-KU Leuven Center for Microbiology, Leuven, Belgium.
KU Leuven Laboratory of Molecular Cell Biology, Leuven, Belgium.
Microb Cell. 2018 Jun 14;5(7):300-326. doi: 10.15698/mic2018.07.638.
Unlike superficial fungal infections of the skin and nails, which are the most common fungal diseases in humans, invasive fungal infections carry high morbidity and mortality, particularly those associated with biofilm formation on indwelling medical devices. Therapeutic management of these complex diseases is often complicated by the rise in resistance to the commonly used antifungal agents. Therefore, the availability of accurate susceptibility testing methods for determining antifungal resistance, as well as discovery of novel antifungal and antibiofilm agents, are key priorities in medical mycology research. To direct advancements in this field, here we present an overview of the methods currently available for determining (i) the susceptibility or resistance of fungal isolates or biofilms to antifungal or antibiofilm compounds and compound combinations; (ii) the efficacy of antifungal and antibiofilm compounds and compound combinations; and (iii) the and performance of anti-infective coatings and materials to prevent fungal biofilm-based infections.
与皮肤和指甲的浅表真菌感染（人类最常见的真菌疾病）不同，侵袭性真菌感染具有很高的发病率和死亡率，尤其是那些与植入式医疗设备上生物膜形成相关的感染。这些复杂疾病的治疗管理常常因对常用抗真菌药物耐药性的增加而变得复杂。因此，拥有准确的药敏试验方法以确定抗真菌耐药性，以及发现新型抗真菌和抗生物膜药物，是医学真菌学研究的关键优先事项。为指导该领域的进展，在此我们概述目前可用于确定以下方面的方法：（i）真菌分离株或生物膜对抗真菌或抗生物膜化合物及化合物组合的敏感性或耐药性；（ii）抗真菌和抗生物膜化合物及化合物组合的疗效；以及（iii）抗感染涂层和材料预防基于真菌生物膜感染的性能。
